This modulation is protected by overexpression of LSH, which can attenuate p53 recruitment to the promoter region of ELAVL1. Studies have revealed a role for LINC00336 as a competing endogenous RNA (ceRNA) to inactivate miR-6852 in lung cancer, thus allowing it to be potential target of lung cancer therapy. Here, ELAVL1 is linked to lung carcinoma.